Michael Trauner - Curriculum Vitae#

Research Interests
  • Dr. Trauner’s main research interests are focused on the molecular mechanisms of bile acid transport and signaling in cholestatic and fatty liver diseases, unravelling the mechanisms of cell injury in cholestatic and fatty liver disease, and develop novel pharmacologic treatments for cholestatic and fatty liver diseases based on novel mechanistic insights from translational research.
  • His work is an excellent example for successful translational research focusing on the one hand on understanding the molecular mechanisms of cholestatic and metabolic liver diseases and on the hand bringing these novel mechanistic insights to clinical applications via investigator-driven Phase II studies and as lead principal investigator in multicenter international phase III trials in the area of Hepatology. His research also bridges our understanding of hepatobiliary transport as basis of liver disease with applications in functional MRI and PET imaging from preclinical mouse models to patients with cholestatic and metabolic liver diseases. Moreover, the work explores the role of bile acids as biomarkers and therapeutics in fatty liver disease including novel therapeutic applications in the field of portal hypertension along the gut liver axis in liver cirrhosis and hepatocellular as well as cholangiocellular carcinoma.
  • Dr. Trauners work has resulted in landmark papers on the molecular pathogenesis of cholestatic liver diseases and the role of bile acids as novel therapeutics in cholestatic and fatty liver diseases with a specific focus on chronic inflammatory bile duct diseases such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).

Education and career history
  • Since 2010 Professor of Medicine, Chair of Gastroenterology and Hepatology, Medical University of Vienna, Austria
  • 2005 – 2010 Professor of Medicine, Experimental and Clinical Hepatology, Medical University of Graz, Austria
  • 2000 – 2005 Associate Professor of Medicine (Tenure), Medical University of Graz, Austria
  • 1998 – 2001 Subspecialty Training in Gastroenterology and Hepatology, Department of Internal Medicine, University of Graz, Austria
  • 1997 – 1998 Residency in Internal Medicine (ctd.) Department of Internal Medicine, Karl Franzens University Graz, Austria
  • 1994 – 1997 Postdoctoral Research Associate, Department of Internal Medicine (Section of Digestive Diseases) and Liver Center, Yale University School of Medicine, New Haven, CT, U.S.A.,
  • 1991 – 1994 Residency in Internal Medicine, Department of Internal Medicine, Karl Franzens University Graz, Austria
  • 1982 – 1991 University education in Medicine, University of Graz, Austria

Invited lectures

More than 200 invited lectures at international scientific meetings (e.g. Annual Meetings and Single Topic Conferences of the American Association for the Study Liver Disease (AASLD), Digestive Disease Week (DDW), Annual Meeting and Monothematic Conferences of the European Association for the Study of the Liver (EASL), European Athorosclerosis Association, Falk Symposia, United European Gastroenterology Week (UEGW)); invited state-of-the-art lectures at Annual Meetings of National Societies for the Study of the Liver (British (2007), Spanish (2008) and Italian (2009))

Ad-Hoc Reviewer for more than 60 international peer-reviewed journals (selection):
American Journal of Physiology, Biochemical and Biophysical Acta, British Journal of Pharmacology, Drug Metabolism and Disposition, FEBS Letters, Gastroenterology, Gut, Hepatology, Journal of Clinical Investigation, Journal of Hepatology , Journal of Lipid Research, Molecular Pharmacology, Nature Medicine, Nature Communications, PLOs Biology
  • Since 2000 Bockus International Society of Gastroenterology
  • Since 1999 Österreichische Gesellschaft für Innere Medizin (Austrian Society of Internal Medicine)
  • Since 1999 European Association for the Study of the Liver
  • Since 1996 American Gastroenterological Association
  • Since 1995 American College of Gastroenterology
  • Since 1995American Association for the Study of Liver Disease
  • Since 1992 Austrian Society for Gastroenterology and Hepatology (ÖGGH), Governing Board since 2000, President from 2014-2016

Editorial Boards (selected):
  • Since 2016 Seminars of Liver Disease (Associate Editor)
  • Since 2009 Hepatology (Associate Editor for two periods)
  • 2010-2014 Gastroenterologie Clinique at Biologique
  • Since 2010 Viszeralmedizin
  • Since 2007 Expert Review of Gastroenterology and Hepatology, The Open Gastroenterology Journal
  • 2006-2014 Gastroenterology
  • 2004-2011 Faculty of 1000 Medicine / Gastroenterology & Hepatology
  • 2004-2011 World Journal of Gastroenterology
  • Since 2003 Liver International
  • 2000-2009 Journal of Hepatology (2004-2009 Associate Editor)

Sources of competitive funding (selection of last 5 years)
  • 2006 – 2011, FWF, 24-nor-ursodeoxycholic acid as novel therapeutic approach to cholangiopathies, € 347.227
  • 2007 - 2017, FWF (SFB30 Lipotoxicity) Role of hepatobiliary bile acid transporters and bile acid-activaed nuclear receptors in the control of hepatic lipid metabolism and defense against lipotoxicity”, € 1.057.368,--
  • 2009 - 2012, GEN-AU-3, Genome-Austria Tissue Bank II (GATiB II), € 345.521,-
  • 2010 - 2013, FFG, Biomarkers for personalized medicine in common metabolic disorders” (Area Leader Hepatology) € 1.880.000,-
  • 2010 - 2013, EU, FP7 (FLIP), Role of hepatic triglyceride lipases in the Progression to NASH, € 340.157,-
  • 2012 - 2014, Bürgermeisterfonds, Impact of fructose consumption on intestinal permeability and its role in the pathogenesis and progression of NAFLD – a pilot study, € 81.985,-
  • 2012 - 2018, FWF (SFB35), Molecular regulation of hepatobiliary ABC transporters in cholestatic liver diseases, € 693.803,-
  • 2013 - 2015, WWTF, Unravelling the pathogenetic mechanisms of fructose consumption as multiple hit in the pathogenesis and progression of non-alcoholic fatty liver disease (NAFLD), € 400.000,--
  • 2013 - 2016, FWF, DK Programm, Inflammation and Immunity, Bile acid as Regulators of Inflammation in Cholestatic Liver Diseases, € 150.480,--
  • 2016 - 2019, FWF Joint Project, (I 1726-B20), MAGL - Monoacylglycerol, a new immun-metabolic therapeutic target for chronic liver diseases, € 300.024,--
  • 2016 - 2019, FWF Joint Project, (I 2755-B30) - DYNAFLOW – “Dynamic bile flow modelling and cellular sensing in primary sclerosing cholangitis, € 249.932,--

International collaboration partners (selection of last 5 years):
  • Hanns-Ulrich Marschall The Sahlgrenska Academy, University of Gothenburg, Sweden
  • Saul J. Karpen Emory University, School of Medicine, Atlanta, USA
  • David D. Moore Baylor Medical College, Houston, USA
  • James L. Boyer Yale Liver Center, New Haven, Connecticut, USA
  • Johan Auwerx University of Lausanne, CH

Imprint Privacy policy « This page (revision-3) was last changed on Tuesday, 10. October 2017, 15:34 by Kaiser Dana
  • operated by